Pharmacogenetic Implications of eNOS Polymorphisms (

Alleles Amino Acid Substitution Animals Biomarkers Cardiovascular Agents / pharmacology Cardiovascular Diseases / drug therapy Cardiovascular System / drug effects Gene Expression Regulation / drug effects Genetic Association Studies Genetic Predisposition to Disease Humans Nitric Oxide / metabolism Nitric Oxide Synthase Type III / genetics Pharmacogenetics Pharmacogenomic Variants Polymorphism, Single Nucleotide Signal Transduction / drug effects
Cardiovascular drug eNOS nitric oxide pharmacogenetics polymorphisms review

Journal

In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809

Informations de publication

Date de publication:
Historique:
received: 21 02 2019
revised: 09 06 2019
accepted: 19 06 2019
entrez: 8 7 2019
pubmed: 8 7 2019
medline: 21 12 2019
Statut: ppublish

Résumé

Endothelial nitric oxide synthase (NOS3 or eNOS) is the enzyme responsible for the highest production of nitric oxide, with the greatest impact on the cardiovascular system, encoded by the eNOS gene, which presents various polymorphisms. ENOS gene polymorphisms play an important role in the response to drugs affecting nitric oxide (NO) signaling. This review discusses the pharmacogenetic impact of eNOS polymorphisms on the response to drugs affecting NO activity: angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, calcium blockers, beta-blockers, diuretics, phosphodiesterase inhibitors, and statins. The identification of biomarkers that accurately predict particular phenotypes is a challenge that needs additional large studies, in different populations. Efforts should be oriented towards a more accurate evaluation of the effects of eNOS genetic variants on biochemical parameters reflecting eNOS gene expression and enzymatic activity, in different diseases, as well as following drug treatment. This approach will allow for a better understanding of the role of eNOS genetic variants in cardiovascular disease progression and for cardiovascular drug therapy optimization.

Identifiants

DOI: 10.21873/invivo.11573 PMID: 31280192 PMC: PMC6689342
pubmed: 31280192
pii: 33/4/1051
doi: 10.21873/invivo.11573
pmc: PMC6689342
doi:

Substances chimiques

Biomarkers 0
Cardiovascular Agents 0
Nitric Oxide 31C4KY9ESH
NOS3 protein, human EC 1.14.13.39
Nitric Oxide Synthase Type III EC 1.14.13.39

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1051-1058

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Références

J Mol Cell Cardiol. 1999 Jan;31(1):51-60
pubmed: 10072715
Circulation. 1999 Jun 8;99(22):2855-7
pubmed: 10359726
Circulation. 1999 Jun 8;99(22):2864-70
pubmed: 10359729
J Pharmacol Exp Ther. 2000 Feb;292(2):606-9
pubmed: 10640297
Hypertension. 2000 Jan;35(1 Pt 2):501-6
pubmed: 10642349
Cardiovasc Res. 1999 Aug 15;43(3):549-61
pubmed: 10690327
Circulation. 2000 Apr 11;101(14):1653-9
pubmed: 10758046
Nat Med. 2000 Sep;6(9):1004-10
pubmed: 10973320
Hum Mol Genet. 2000 Nov 1;9(18):2629-37
pubmed: 11063722
Circulation. 2001 Feb 13;103(6):799-805
pubmed: 11171786
Hypertension. 2001 Mar;37(3):943-8
pubmed: 11244022
Atherosclerosis. 2001 Apr;155(2):347-57
pubmed: 11254905
Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712-9
pubmed: 11701455
Circ Res. 2001 Nov 9;89(10):866-73
pubmed: 11701613
J Hypertens. 2002 Jan;20(1):71-8
pubmed: 11791028
Circulation. 2002 Jan 22;105(3):393-6
pubmed: 11804998
Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):e1-4
pubmed: 12006409
Pharmacogenetics. 2002 Jul;12(5):407-13
pubmed: 12142730
Nitric Oxide. 2002 Nov;7(3):149-64
pubmed: 12381413
Eur Heart J. 2002 Dec;23(24):1955-62
pubmed: 12473258
J Mol Med (Berl). 2002 Dec;80(12):802-7
pubmed: 12483466
Pharmacogenetics. 2003 Jan;13(1):7-17
pubmed: 12544508
Am J Hypertens. 2003 Feb;16(2):123-8
pubmed: 12559678
N Engl J Med. 2003 Feb 6;348(6):538-49
pubmed: 12571262
J Atheroscler Thromb. 2003;10(1):43-7
pubmed: 12621164
Circulation. 2003 Apr 1;107(12):1598-602
pubmed: 12668492
Urology. 2003 Jul;62(1):152-7
pubmed: 12837457
Cardiovasc Res. 2003 Oct 1;59(4):844-53
pubmed: 14553824
Am J Hypertens. 2003 Oct;16(10):834-9
pubmed: 14553962
J Pharmacol Exp Ther. 2003 Dec;307(3):1171-8
pubmed: 14560036
Hypertension. 2003 Dec;42(6):1206-52
pubmed: 14656957
JAMA. 2003 Dec 3;290(21):2805-16
pubmed: 14657064
Circulation. 2004 Jan 20;109(2):e7-8; author reply e7-8
pubmed: 14734510
Stroke. 2004 Jun;35(6):1305-9
pubmed: 15073390
Am J Hypertens. 2004 Jul;17(7):553-9
pubmed: 15233973
Am J Hypertens. 2004 Jul;17(7):560-7
pubmed: 15233974
J Hypertens. 2005 Mar;23(3):589-96
pubmed: 15716701
Annu Rev Pharmacol Toxicol. 2005;45:89-118
pubmed: 15822172
Pharmacogenet Genomics. 2005 May;15(5):329-36
pubmed: 15864134
Curr Opin Lipidol. 2005 Dec;16(6):624-9
pubmed: 16276239
Nat Rev Drug Discov. 2005 Dec;4(12):977-87
pubmed: 16341063
Am J Physiol Cell Physiol. 2006 Nov;291(5):C803-16
pubmed: 16738003
Int J Impot Res. 2007 Mar-Apr;19(2):149-53
pubmed: 16871271
Atherosclerosis. 2007 Aug;193(2):438-44
pubmed: 16938300
Hypertension. 2006 Oct;48(4):700-10
pubmed: 16940230
Free Radic Biol Med. 2006 Oct 1;41(7):1044-9
pubmed: 16962929
Handb Exp Pharmacol. 2006;(176 Pt 1):213-54
pubmed: 16999221
Am J Epidemiol. 2006 Nov 15;164(10):921-35
pubmed: 17018701
J Hypertens. 2006 Dec;24(12):2393-7
pubmed: 17082721
Physiol Rev. 2007 Jan;87(1):315-424
pubmed: 17237348
FASEB J. 2007 Sep;21(11):2655-63
pubmed: 17449720
J Hypertens. 2007 Sep;25(9):1763-74
pubmed: 17762636
Cardiovasc Drug Rev. 2007 Fall;25(3):280-8
pubmed: 17919260
Nitric Oxide. 2008 Feb;18(1):19-27
pubmed: 17936042
Anticancer Res. 2007 Sep-Oct;27(5B):3465-70
pubmed: 17972502
Pharmacogenomics. 2007 Dec;8(12):1723-34
pubmed: 18086002
J Biol Chem. 2008 May 23;283(21):14685-93
pubmed: 18390539
Mol Biol Cell. 2008 Sep;19(9):3997-4005
pubmed: 18614799
Am J Hypertens. 2008 Nov;21(11):1251-7
pubmed: 18772860
Gan To Kagaku Ryoho. 2008 Oct;35(10):1649-53
pubmed: 18931564
Acta Physiol (Oxf). 2009 Jun;196(2):193-222
pubmed: 19220204
Am J Hypertens. 2009 Jul;22(7):748-53
pubmed: 19407804
Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1156-60
pubmed: 19605779
Basic Clin Pharmacol Toxicol. 2010 May;106(5):357-61
pubmed: 20210789
J Clin Pharmacol. 2012 Jan;52(1):102-9
pubmed: 21406601
N Engl J Med. 2011 Mar 24;364(12):1144-53
pubmed: 21428770
Arq Bras Cardiol. 2011 Feb;96(2):e27-34
pubmed: 21445464
J Endocrinol. 2011 Sep;210(3):271-84
pubmed: 21642378
Pharmacogenomics J. 2013 Apr;13(2):189-96
pubmed: 22064666
Br J Clin Pharmacol. 2012 Jul;74(1):141-6
pubmed: 22283728
PLoS One. 2012;7(3):e34217
pubmed: 22470539
Eur J Clin Pharmacol. 2013 Feb;69(2):167-77
pubmed: 22706620
Int J Cardiol. 2013 Sep 1;167(5):1677-87
pubmed: 23121914
Cardiovasc Drugs Ther. 2013 Apr;27(2):171-9
pubmed: 23224653
Circulation. 2013 Feb 12;127(6):749-56
pubmed: 23401116
Nitric Oxide. 2013 Sep 1;33:83-7
pubmed: 23876348
Pharmacogenomics J. 2013 Dec;13(6):481-3
pubmed: 23999596
Pharmacogenomics. 2014 Aug;15(11):1519-38
pubmed: 25303302
Gene. 2016 Jan 10;575(2 Pt 3):584-99
pubmed: 26428312
J Pharmacol Sci. 2015 Oct;129(2):83-94
pubmed: 26499181
Nitric Oxide. 2017 Feb 28;63:39-51
pubmed: 27569446
Basic Clin Pharmacol Toxicol. 2017 Mar;120(3):284-291
pubmed: 27696692
Free Radic Biol Med. 2017 Aug;109:4-10
pubmed: 27988339
Oncotarget. 2017 Mar 7;8(10):16887-16898
pubmed: 28129643
Pharmacogenomics. 2017 Apr;18(6):571-583
pubmed: 28358601
Genet Mol Res. 2017 May 04;16(2):null
pubmed: 28481400
Genet Mol Res. 2017 Sep 21;16(3):null
pubmed: 28973724
Per Med. 2017 Nov;14(6):531-549
pubmed: 29749858
Circulation. 1995 Jan 1;91(1):96-102
pubmed: 7528648
J Biol Chem. 1993 Aug 15;268(23):17478-88
pubmed: 7688726
N Engl J Med. 1995 Feb 23;332(8):481-7
pubmed: 7830728
N Engl J Med. 1995 Feb 23;332(8):488-93
pubmed: 7830729
Circulation. 1997 Jan 7;95(1):76-82
pubmed: 8994420
Atherosclerosis. 1996 Nov 15;127(1):43-7
pubmed: 9006803
Circulation. 1997 Mar 4;95(5):1126-31
pubmed: 9054840
J Biol Chem. 1997 Dec 12;272(50):31725-9
pubmed: 9395516
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3147-53
pubmed: 9409304
Biochem Biophys Res Commun. 1998 Apr 7;245(1):190-3
pubmed: 9535806
Circulation. 1998 Mar 31;97(12):1129-35
pubmed: 9537338
Hypertension. 1998 Jul;32(1):3-8
pubmed: 9674630

Auteurs

Angela Cozma (A)

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
4th Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Adriana Fodor (A)

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
Clinical Center of Diabetes, Nutrition and Metabolic Disease, Cluj-Napoca, Romania.

Olga Hilda Orasan (OH)

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
4th Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Romana Vulturar (R)

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
Department of Cell Biology, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Dorel Samplelean (D)

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
4th Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Vasile Negrean (V)

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
4th Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Crina Muresan (C)

University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca, Faculty of Food Science &Technology, Cluj-Napoca, Romania.

Ramona Suharoschi (R)

University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca, Faculty of Food Science &Technology, Cluj-Napoca, Romania ramona.suharoschi@usamvcluj.ro.

Adela Sitar-Taut (A)

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
4th Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Allèles › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Phénomènes génétiques › Mutagenèse › Substitution d'acide aminé › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Eucaryotes › Animaux › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents cardiovasculaires › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Maladies cardiovasculaires › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Système cardiovasculaire › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Études d'associations génétiques › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Phénomènes génétiques › Génotype › Prédisposition génétique à une maladie › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Oxydes › Oxydes d'azote › Monoxyde d'azote › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxidoreductases acting on CH-NH2 group donors › Amino-acid oxidoreductases › Nitric oxide synthase › Nitric oxide synthase type III › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Professions de santé › Pharmacologie › Pharmacogénétique › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Variants pharmacogénomiques › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Polymorphisme de nucléotide simple › Pharmacogenetic Implications of eNOS Polymorphisms (
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Pharmacogenetic Implications of eNOS Polymorphisms (